Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program

2015 ◽  
Vol 85 (6) ◽  
pp. 952-958 ◽  
Author(s):  
Roberto Diletti ◽  
Hector M. Garcia-Garcia ◽  
Christos Bourantas ◽  
Nicolas M. Van Mieghem ◽  
Robert Jan van Geuns ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Clinical Outcomes ◽  
Body Mass ◽  
Stent Implantation ◽  
Second Generation ◽  
Drug Eluting Stent ◽  
Drug Eluting

scholarly journals Long‐term clinical outcomes after drug eluting stent implantation with and without stent overlap

2021 ◽  
Author(s):  
J. J. Coughlan ◽  
Alp Aytekin ◽  
Tobias Koch ◽  
Jens Wiebe ◽  
Tobias Lenz ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Stent Implantation ◽  
Drug Eluting Stent ◽  
Drug Eluting

P45945-years clinical outcomes of patients underwent percutaneous coronary intervention for calcified lesions with rotational atherectomy and second-generation drug eluting stent

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
K Ogata ◽  
H Koiwaya ◽  
K Shinzato ◽  
Y Goriki ◽  
G Yoshioka ◽  
...  
Keyword(s):  
Risk Factors ◽  
Percutaneous Coronary Intervention ◽  
Clinical Outcomes ◽  
Second Generation ◽  
Coronary Intervention ◽  
Drug Eluting Stent ◽  
Diabetic Mellitus ◽  
Percutaneous Coronary ◽  
Drug Eluting

Abstract Background Percutaneous coronary Intervention (PCI) with rotational atherectomy (RA) was useful for severe calcified lesions. However, the long-term clinical outcomes of PCI with second-generation drug eluting stent (DES) following RA has been still unclear. Purpose The purpose of this study was to investigate the long-term clinical outcomes of RA followed by second-generation DES. Methods We retrospectively enrolled 254 consecutive patients treated with second-generation DES following RA. The primary outcome was the cumulative 5-year incidence of MACE, defined as cardiac death, myocardial infarction, clinically-driven target lesion revascularization and definite stent thrombosis. Results The incidence of MACE was 22.8% at 5-years. Multivariate analysis showed 3 predictors of MACE, hemodialysis, diabetic mellitus and extremely angulated lesions (>90°).Significantly higher MACE was observed in the high-risk (≥2 risk factors) group, compared with the low-risk (2< risk factors) group (68.7% vs. 18.7%, P<0.001, Figure). Multivariate analysis for MACE at 5 year Hazard ratio (95% Confidence Interval) P-value Diabetic Mellitus 2.58 (1.35–4.91) 0.004 Hemodialysis 4.57 (1.64–12.76) 0.004 extremely angulated (>90°) 3.08 (1.06–8.93) 0.04 Kaplan-Meier curves for 5-years MACE Conclusions The long-term clinical outcomes of PCI for severely calcified lesions was acceptable. However, the clinical outcomes of patients classified high risk cohort was unsatisfactory.

scholarly journals Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis

2019 ◽  
Vol 12 (6) ◽  
Author(s):  
Shoichi Kuramitsu ◽  
Masanobu Ohya ◽  
Tomohiro Shinozaki ◽  
Hiromasa Otake ◽  
Kazunori Horie ◽  
...  
Keyword(s):  
Risk Factors ◽  
Clinical Outcomes ◽  
Stent Thrombosis ◽  
Second Generation ◽  
Drug Eluting Stent ◽  
Drug Eluting

Impact of Intravascular Ultrasound–Guided Optimal Stent Expansion on 3-Year Hard Clinical Outcomes

2021 ◽  
Vol 14 (10) ◽  
Author(s):  
Yong-Joon Lee ◽  
Jun-Jie Zhang ◽  
Gary S. Mintz ◽  
Sung-Jin Hong ◽  
Chul-Min Ahn ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Intravascular Ultrasound ◽  
Stent Implantation ◽  
Hazard Ratio ◽  
Drug Eluting Stent ◽  
Lumen Area ◽  
Ultrasound Guided ◽  
Stent Expansion ◽  
Drug Eluting

Background: Although stent underexpansion on intravascular ultrasound (IVUS) has been a major predictor for adverse outcomes in previous studies, these studies have primarily focused on angiographic restenosis or repeat revascularization with short-term follow-up. This study sought to evaluate the long-term benefit of different criteria for IVUS-defined optimal stent expansion on hard clinical outcomes. Methods: From the pooled data of 2 randomized trials, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions) that compared IVUS- versus angiography-guided drug-eluting stent implantation, a total of 1254 patients with IVUS-guided drug-eluting stent implantation into 1484 long lesions (implanted stent length, ≥28 mm) were included. Different criteria for IVUS-defined optimal stent expansion based on minimum stent area (MSA) as an absolute measure or MSA relative to reference lumen area were applied and validated. The primary end point was composite of cardiac death, target lesion–related myocardial infarction, or stent thrombosis at 3 years. Results: The rate of the primary end point was lower in patients with optimal stent expansion versus those without optimal stent expansion according to 3 IVUS-defined optimal stent expansion criteria: MSA >5.5 mm 2 (0.5% versus 2.2%; hazard ratio, 0.21 [95% CI, 0.06–0.75]; P =0.008), MSA >5.0 mm 2 (0.6% versus 2.6%; hazard ratio, 0.24 [95% CI, 0.09–0.68]; P =0.003), and MSA/distal reference lumen area >90% (0.5% versus 2.4%; hazard ratio, 0.32 [95% CI, 0.12–0.88]; P =0.019). Achieving other relative expansion criteria, MSA/distal reference lumen area >100% or 80% or MSA/average reference lumen area >90% or 80%, was not associated with a reduction in hard clinical events. Conclusions: In patients undergoing IVUS-guided drug-eluting stent implantation for long lesions, achieving optimal stent expansion of MSA >5.5 mm 2 , >5.0 mm 2 , or MSA/distal reference lumen area >90% was associated with improved long-term hard clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document